RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE) – Synteract, een innovatieve CRO die samenwerkt met biotech- en farmaceutische bedrijven om nieuwe geneesmiddelen op de markt te brengen, heeft Clindata’s biometrische divisie voor menselijke gezondheid overgenomen om te voldoen aan de marktvraag naar meer aanpasbare oplossingen voor biometrische diensten. Deze acquisitie breidt de bestaande wereldwijde voetafdruk van Synteract uit naar Azië-Pacific en Afrika, en biedt een ander kerncentrum voor biometrische services, complementair aan de activiteiten die het in Europa en de VS uitvoert.

Clindata, met kantoren in Bloemfontein, Zuid-Afrika en Colombo, Sri Lanka, is een klinische onderzoeksorganisatie voor biometrie en biedt biostatistiek, programmering en gegevensbeheer in alle fasen van de ontwikkeling van geneesmiddelen. De veterinaire divisie van Clindata zal blijven opereren onder de naam Clindata, onafhankelijk van Synteract, terwijl de divisie Human Health Biometrics zal combineren met Synteract. De combinatie van Clindata’s ervaren team van biometrische professionals met dat van Synteract verbetert de biometrische mogelijkheden van Synteract verder als onderdeel van zijn geïntegreerd, full-service programma; speciale FSP solution, of als een zelfstandige biometrische service om de interne mogelijkheden van klanten te vergroten.

Synteract Expands into Asia Pacific and South Africa Through Acquisition of Specialty Biometrics CRO

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint into Asia Pacific and Africa, and offers another core biometrics services hub, complementary to those it operates in Europe and the U.S.

Clindata, with offices in Bloemfontein, South Africa, and Colombo, Sri Lanka, is a biometrics Clinical Research Organization, offering biostatistics, programming and data management services across all phases of drug development. Clindata’s Veterinary division will continue to operate under the Clindata name, independently from Synteract, while the Human Health Biometrics division will combine with Synteract. The combination of Clindata’s experienced team of biometrics professionals with that of Synteract’s further enhances Synteract’s biometrics capabilities as part of its integrated, full-service program; dedicated FSP solution, or as a standalone biometrics service to augment clients’ in-house capabilities.

“Like Synteract, Clindata is known for high quality service delivery, collaboration, agility and expertise of its teams,” says Synteract CEO Steve Powell. “Innovative changes in biometrics are transforming the ways in which clinical study data is collected, integrated and analyzed. Rich patient data gives researchers insights into disease progression and response to therapy in ways we have not seen before. This is an exciting time to be adding even more expertise to our teams and will allow us to deliver global biometrics services covering every time-zone.”

With a wealth of data management, CDISC, biostatistics and SAS experience, the Clindata team have significant experience running Phase I-IV studies across the complementary therapeutic areas of Synteract. Clindata CEO, Theo Erasmus, adds, “With our combined biometrics capabilities, clients will benefit from a complete service offering incorporating all data components from research, advice on study design, document planning to PK analyses and results interpretation, as well as global capabilities, all provided by one integrated CRO. We are glad to be joining Synteract and creating a world class delivery team.”

Synteract is a portfolio company of Amulet Capital Partners, LP. Financial terms are not being disclosed.

About Synteract

“Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development with multi-disciplinary teams and deep expertise. Synteract has conducted nearly 4,000 studies on six continents and has contributed to more than 240 product approvals. Synteract offers notable depth of expertise in oncology, dermatology, general medicine, neuroscience, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter.

About Clindata

Founded in 2012, Clindata is a Contract Research Organization (CRO) based in South Africa. The Clindata core team of experienced, dedicated staff has worked for in the CRO and health industry for many years. We bring a wealth of Data Management, CDISC, Biostatistics and SAS experience. Our team members have significant experience gained from working on studies of various phases and throughout an array of therapeutic areas.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005231/en/

Contacts

Beth Walsh

beth@clearpointagency.com
760-230-2424